Ghana commissioned a national Human Identification Laboratory and new vaccine R&D laboratories at Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, after the August 6, 2025 military helicopter crash killed eight eminent Ghanaians.
President John Dramani Mahama, who inaugurated the facilities, said Ghana had to send tissue samples recovered from the crash site to South Africa for analysis.
He called it a day of shame that Ghana could not carry out its own DNA analysis in-country.
The consequence was felt most directly by families, who waited several days for identification of their relatives after the crash.
Equipment gap, not expertise gap
Health Minister Kwabena Mintah Akandoh said Ghana had qualified DNA scientists but lacked the specialised equipment to test locally. The laboratory was established on the President’s directive after the helicopter disaster, he said.
The DNA Laboratory provides domestic infrastructure for human DNA testing and identification. It will provide local forensic, paternity, maternity and inheritance testing, reducing reliance on foreign laboratories.
Mahama said the facility would support forensic investigations and help resolve paternity disputes.
It was commissioned alongside new vaccine research and development laboratories, which include an mRNA Expression Laboratory and a Protein Expression Laboratory.
Vaccine production timeline
National Vaccine Institute CEO Dr Sodzi Sodzi-Tettey said the first of three bulk substances needed for the targeted vaccine production is already in Ghana at Atlantic LifeSciences.
Akandoh said the first vaccines bottled in Ghana are expected on the market in 2027.
Akandoh said the new vaccine research laboratories would give Ghanaian scientists tools to develop vaccine candidates locally.
He said collaboration among the National Vaccine Institute, the Food and Drugs Authority and research institutions could move Ghana from vaccine discovery to clinical trials and local vaccine production.
Sodzi-Tettey said the government is pursuing long-term procurement arrangements to guarantee a market for locally manufactured vaccines.
Funding and regional disease threats
Mahama announced that the Government had allocated US$1 billion to the pharmaceutical sector under the Seventh Pillar of the New Economy Programme. The investment would support pharmaceutical and biomanufacturing hubs in the Eastern, Central and Volta regions.
The President said West Africa and the wider African continent face recurrent threats from infectious diseases including Mpox, Lassa fever, Ebola virus disease and Marburg virus disease.
The facilities were established in response to the August 6, 2025 crash, which required DNA samples to be sent to South Africa for identification.





Comments